Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer

BACKGROUND: Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic breast cancer (LA/mBC), with approval based on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Savill, Kristin M Zimmerman, Ivanova, Jasmina, Asgarisabet, Parisa, Falkenstein, Angelica, Balanean, Alexandrina, Niyazov, Alexander, Ryan, Joanne C, Kish, Jonathan, Gajra, Ajeet, Mahtani, Reshma L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166159/
https://www.ncbi.nlm.nih.gov/pubmed/36952230
http://dx.doi.org/10.1093/oncolo/oyad021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166159/
https://www.ncbi.nlm.nih.gov/pubmed/36952230
http://dx.doi.org/10.1093/oncolo/oyad021

Ejemplares similares